We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Prototype CTC Collection Device Tested Successfully in Model

By LabMedica International staff writers
Posted on 08 Apr 2019
A novel, wearable device for continuous isolation of circulating tumor cells (CTCs) from a peripheral vein was tested successfully in a dog model of human cancer.

CTCs are now an established biomarker for prognosis in patients with various carcinomas. More...
However, current CTC isolation technologies rely on small blood volumes from a single venipuncture limiting the number of captured CTCs. This produces statistical variability and inaccurate reflection of tumor cell heterogeneity.

To improve this situation, investigators at the University of Michigan (Ann Arbor, USA) and collaborators at Colorado State University (Fort Collins, USA) designed an in vivo indwelling intravascular CTC isolation device to continuously collect CTCs directly from a peripheral vein. The system would return the remaining blood products after CTC enrichment, permitting interrogation of larger blood volumes than could be obtained by classic phlebotomy over a prolonged period of time.

The investigators produced a prototype wearable device that utilized novel protocols for mixing blood with the clot-inhibiting drug heparin and that employed sterilization methods for killing bacteria without harming the cell-targeting antibodies on the chip. The chip itself incorporated the nanomaterial graphene oxide to create a dense matrix of antibody-tipped molecular chains, which enabled it to trap more than 80% of the cancer cells from the whole blood that flowed across it.

The investigators reported in the April 1, 2019, online edition of the journal Nature Communications that they had validated the system in canine models. Results demonstrated the capability for screening 1–2% of the animal's entire blood supply over a period of two hours. This approach yielded a substantial increase in CTC capture, compared with serial blood draws.

"Nobody wants to have a biopsy. If we could get enough cancer cells from the blood, we could use them to learn about the tumor biology and direct care for the patients. That is the excitement of why we are doing this," said senior author Dr. Daniel F. Hayes, professor of internal medicine at the University of Michigan. "This is the epitome of precision medicine, which is so exciting in the field of oncology right now."

Related Links:
University of Michigan
Colorado State University


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Cytomegalovirus Real-Time PCR Test
Quanty CMV Virus System
New
HbA1c Test
HbA1c Rapid Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: AI-analyzed images from the FDM microscope show platelet clumps in motion (Photo courtesy of Hirose et al CC-BY-ND)

AI Microscope Spots Deadly Blood Clots Before They Strike

Platelets are small blood cells that act as emergency responders in the body, rushing to areas of injury to help stop bleeding by forming clots. However, sometimes platelets can overreact, leading to complications.... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.